Thursday, March 12, 2026
News Health
  • Health News
  • Hair Products
  • Nutrition
    • Weight Loss
  • Sexual Health
  • Skin Care
  • Women’s Health
    • Men’s Health
No Result
View All Result
  • Health News
  • Hair Products
  • Nutrition
    • Weight Loss
  • Sexual Health
  • Skin Care
  • Women’s Health
    • Men’s Health
No Result
View All Result
HealthNews
No Result
View All Result
Home Health News

Wegovy pill approved by US FDA for weight loss

December 23, 2025
in Health News
Share on FacebookShare on Twitter


The US Food and Drug Administration (FDA) has approved a pill version of the weight-loss drug Wegovy, according to pharmaceutical giant Novo Nordisk.

It is the first pill of its kind to receive approval from the regulator, marking a new era for weight-loss drugs.

Wegovy’s Danish makers Novo Nordisk said the once-daily pill was a “convenient option” to the injectable and would provide the same weight loss as the shot. It comes after Wegovy was approved by the FDA specifically for weight loss.

Others like Ozempic, which has similar weight-loss effects, were primarily approved for the treatment of Type 2 diabetes.

The BBC has contacted the FDA for comment.

The Wegovy pill showed an average weight loss of 16.6% during Novo Nordisk’s trials, the firm said on Monday.

A third of around 1,300 participants experienced 20% or greater weight loss in the same trial, it added.

The pill is expected to be launched in the US in early January 2026.

“Patients will have a convenient, once-daily pill that can help them lose as much weight as the original Wegovy injection,” said Mike Doustdar, the firm’s chief executive.

The pill version of Wegovy could give Novo Nordisk’s sales a boost after a challenging year which saw its shares slide as it warned over its profits.

The company has faced intense competition in the weight-loss market from rival drugmakers like Eli Lilly.

Novo Nordisk’s shares rose by almost 10% in after-hours trade in New York after the announcement.



Source link : https://www.bbc.com/news/articles/ce86le5dyxyo?at_medium=RSS&at_campaign=rss

Author :

Publish date : 2025-12-23 01:29:00

Copyright for syndicated content belongs to the linked Source.

Previous Post

Once-Weekly Oral Combo for HIV Maintains High Rates of Virologic Suppression

Next Post

Apremilast Shows Sustained Benefit for Genital Psoriasis

Related Posts

Health News

Inhaled Vasodilator Slows Lung Function Decline in Idiopathic Pulmonary Fibrosis

March 11, 2026
Health News

Goodbye FAERS? FDA Launches New Combined Adverse Event Database

March 11, 2026
Health News

Lead Suits Cut Physician Radiation Exposure for Interventional Cardiology Cases

March 11, 2026
Health News

Traditional Medicare Enrollees Paid Billions More in Premiums Due to MA Overpayments

March 11, 2026
Health News

FDA Warns GLP-1 Maker Over Failure to Properly Report Deaths, Strokes

March 11, 2026
Health News

Apixaban Snags a Win in Head-to-Head Trial of Direct Oral Anticoagulants

March 11, 2026
Load More

Inhaled Vasodilator Slows Lung Function Decline in Idiopathic Pulmonary Fibrosis

March 11, 2026

Goodbye FAERS? FDA Launches New Combined Adverse Event Database

March 11, 2026

Lead Suits Cut Physician Radiation Exposure for Interventional Cardiology Cases

March 11, 2026

Traditional Medicare Enrollees Paid Billions More in Premiums Due to MA Overpayments

March 11, 2026

FDA Warns GLP-1 Maker Over Failure to Properly Report Deaths, Strokes

March 11, 2026

Apixaban Snags a Win in Head-to-Head Trial of Direct Oral Anticoagulants

March 11, 2026

Drug Cuts Treatment Modifications From Chemotherapy-Induced Thrombocytopenia

March 11, 2026

GLP-1 Drugs May Benefit Cancer Patients With Brain Lesions

March 11, 2026
Load More

Categories

Archives

March 2026
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
3031  
« Feb    

© 2022 NewsHealth.

No Result
View All Result
  • Health News
  • Hair Products
  • Nutrition
    • Weight Loss
  • Sexual Health
  • Skin Care
  • Women’s Health
    • Men’s Health

© 2022 NewsHealth.

Go to mobile version